FFCD - Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study.

Nal-IRI/LV5-FU versus paclitaxel as second-line therapy in patients with metastatic esophageal squamous cell carcinoma (OESIRI-PRODIGE 62): A FFCD multicenter, randomized, phase II study.

Auteurs

D. Tougeron, L. Mineur, A. Zaanan, M. Kadi, C. Poisson Ligeza, V. Bourgeois, J. Martin-Babau, A. Fadin, V. Jestin Le Tallec, V. Le Brun-Ly, O. Dubreuil, F. Khemissa, E. Thimonier, O. Bouché, A. Lièvre, F. Di Fiore, T. Lecomte, J. Desrame, C. Lepage, V. Hautefeuille

Journal / Conférence

ESMO

Type de publication

Poster

Etude

PRODIGE 62 - OESIRI

Localisation

Oesophage